Drug therapy for thyroid associated ophthalmopathy

doi:10.3760/cma.j.cn441417-20240814-06010

Abstract

Abstract:

Thyroid-associated ophthalmopathy is a thyroid-related organautoimmune disease. It mainly occurs in patients with hyperthyroidsm, but may occur in patients with euthyroidism and subclinical or overt hypothyroidism. The current treatment is mainly drug therapy, but there are often adverse reactions in the application of drug therapy. This article reviews the thyroid related ophthalmic drugs, so as to provide references for the patients' treatment and nursing care.

Key words:

摘要：

甲状腺相关眼病多见于甲亢患者，但也会发生在甲状腺功能正常、亚临床或显性甲减患者中，是一种与甲状腺有关的器官自身免疫疾病。目前，甲状腺相关眼病治疗多以药物治疗为主，但在药物治疗中常会出现相关不良反应。本文对甲状腺相关眼病的药物治疗进行综述，为甲状腺相关眼病患者治疗及护理提供参考。

关键词:

甲状腺相关眼病, 自身免疫疾病, 药物治疗, 进展

Chen Xiuzhu, Zhang Kai, Wei Yanxiao, Cong Chenyang.

Drug therapy for thyroid associated ophthalmopathy [J]. International Medicine and Health Guidance News, 2025, 31(6): 927-929.

陈秀珠张凯韦岩笑丛晨阳.

甲状腺相关眼病的药物治疗研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 927-929.

References

[1] Ponto KA, Binder H, Diana T, et al. Prevalence, phenotype, and psychosocial well-being in euthyroid/hypothyroid thyroid-associated orbitopathy[J].Thyroid,2015,25(8):942-948.DOI:10.1089/thy.2015.0031.
[2] Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid Eye disease[J].N Engl J Med,2020,382(4):341-352.DOI:10.1056/NEJMoa1910434.
[3] Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of graves orbitopathy[J].Nat Rev Endocrinol,2020,16(2):104-116.DOI:10.1038/s41574-019-0305-4.
[4] Dolman PJ. Dysthyroid optic neuropathy: evaluation and management[J].J Endocrinol Invest,2021,44(3):421-429.DOI:10.1007/s40618-020-01361-y.
[5] Potvin ARGG, Pakdel F, Saeed P. Dysthyroid optic neuropathy[J].Ophthalmic Plast Reconstr Surg,2023,39(6S):S65-S80.DOI:10.1097/IOP.0000000000002555.
[6] Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 european thyroid association/european group on graves' orbitopathy guidelines for the management of graves' orbitopathy[J].Eur Thyroid J,2016,5(1):9-26.DOI:10.1159/000443828.
[7] Rotondo Dottore G, Chiarini R, De Gregorio M, et al. Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves' orbitopathy[J].Endocrine,2017,58(2):386-389.DOI:10.1007/s12020-016-1226-9.
[8] Xu B, Wu D, Ying H, et al. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with graves' disease[J].Turk J Med Sci,2019,49(3):715-722.DOI:10.3906/sag-1808-67.
[9] Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild graves' orbitopathy[J].N Engl J Med,2011,364(20):1920-1931.DOI:10.1056/NEJMoa1012985.
[10] Hall AJH, Topliss DJ. Medical and surgical treatment of thyroid eye disease[J].Intern Med J,2022,52(1):14-20.DOI:10.1111/imj.15067.
[11] Winther KH, Rayman MP, Bonnema SJ, et al. Selenium in thyroid disorders - essential knowledge for clinicians[J].Nat Rev Endocrinol,2020,16(3):165-176.DOI:10.1038/s41574-019-0311-6.
[12] Li X, Li S, Fan W, et al. Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review[J].Int Ophthalmol,2023,43(4):1437-1449.DOI:10.1007/s10792-022-02537-6.
[13] Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial[J].Lancet Diabetes Endocrinol,2018,6(4):299-309.DOI:10.1016/S2213-8587(18)30021-4.
[14] Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for graves' orbitopathy: efficacy and morbidity[J].J Clin Endocrinol Metab,2011,96(2):320-332.DOI:10.1210/jc.2010-1962.
[15] Zhu W, Ye L, Shen L, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy[J].J Clin Endocrinol Metab,2014,99(6):1999-2007.DOI:10.1210/jc.2013-3919.
[16] Gao G, Dai J, Qian Y, et al. Meta-analysis of methylprednisolone pulse therapy for graves' ophthalmopathy[J].Clin Exp Ophthalmol,2014,42(8):769-777.DOI:10.1111/ceo.12317.
[17] Smith TJ. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy[J].Best Pract Res Clin Endocrinol Metab,2020,34(1):101383.DOI:10.1016/j.beem.2020.101383.
[18] Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[19] Smith TJ. Teprotumumab in thyroid-associated ophthalmopathy: rationale for therapeutic insulin-like growth factor-I receptor inhibition[J].J Neuroophthalmol,2020,40(1):74-83.DOI:10.1097/WNO.0000000000000890.
[20] Smith TJ, Hegedus L. Graves' disease[J].N Engl J Med,2016,375(16):1552-1565.DOI:10.1056/NEJMra1510030.
[21] Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-resistant graves' orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience[J].J Clin Med,2021,10(4):706.DOI:10.3390/jcm10040706.
[22] Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves' orbitopathy[J].Ophthalmic Plast Reconstr Surg,2014,30(2):162-167.DOI:10.1097/IOP.0000000000000037.
[23] Copperman T, Idowu OO, Kersten RC, et al. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery[J].Ophthalmic Plast Reconstr Surg,2019,35(3):e64-e66.DOI:10.1097/IOP.0000000000001346.
[24] González-García A, Sales-Sanz M. Treatment of graves' ophthalmopathy[J].Med Clin (Barc),2021,156(4):180-186.DOI:10.1016/j.medcli.2020.07.031.
[25] Allison AC. Mechanisms of action of mycophenolate mofetil[J].Lupus,2005,14 Suppl 1:s2-s8.DOI:10.1191/0961203305lu2109oa.
[26] Chakrabarti K, Frame D, Al Abbas M, et al. The use of mycophenolate mofetil area under the curve[J].Curr Opin Rheumatol,2021,33(3):221-232.DOI:10.1097/BOR.0000000000000799.
[27] Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe graves' orbitopathy[J].Clin Endocrinol (Oxf),2017,86(2):247-255.DOI:10.1111/cen.13170.
[28] Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial[J].Lancet Diabetes Endocrinol,2018,6(4):287-298.DOI:10.1016/S2213-8587(18)30020-2.
[29] Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 european group on graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[30] Stoynova MA, Shinkov AD, Novoselski MT, et al. Changes in therapeutic response, ocular manifestations of graves' orbitopathy and quality of life during the first year after orbital radiotherapy[J].Int Ophthalmol,2023,43(11):4305-4314.DOI:10.1007/s10792-023-02842-8.
[31] Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy[J].N Engl J Med,1989,321(20):1353-1359.DOI:10.1056/NEJM198911163212002.
[32] Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy[J]. Invest Ophthalmol Vis Sci,2014,55(3):1735-1748.DOI:10.1167/iovs.14-14002.